Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy.
Read the full article on WikipediaSymptomatic obstructive hypertrophic cardiomyopathy Clinical criteria: Treatment Phase: Subsequent continuing treatment - Maintenance treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction, AND Patient must be undergoing concomitant treatment with at least one of: (i) a beta-blocker (ii) non-dihydropyridine calcium channel blocker, unless at least one of the following is present: (a) a contraindication to beta-blocker and/or non-dihydropyridine calcium channel blocker therapy as listed in the TGA approved Product Information; (b) an intolerance to beta-blocker and/or non-dihydropyridine calcium channel blocker therapy, AND Patient must have a current left ventricular ejection fraction (LVEF) of no less than 50%, AND Patient must have demonstrated a response after at least 6 months on the optimal dose of mavacamten treatment defined as an improvement in at least one of the following: (i) symptoms, (ii) quality of life, (iii) exercise capacity, (iv) peak left ventricular outflow tract (LVOT) gradient. Treatment criteria: Must be treated by a cardiologist; OR Must be treated by a consultant physician with experience in the management of hypertrophic cardiomyopathy.
Working under the parallel aged-care framework? Aged-care equivalent →